The prospects of an oral obesity candidate used as a monotherapy or combination therapy is in question after Kallyope Inc. posted disappointing phase II data on a government website, indicating that its lead candidate, K-757, failed to meet all endpoints.
Novo Nordisk A/S has exercised an option to license a ligand identified by Kallyope Inc. for further development, including as a potential new approach for the treatment of obesity.
Sosei Group Corp. and Kallyope Inc. have announced the successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal (GI) diseases. The nominated target will advance into a structure-based drug discovery program.
Kallyope Inc. patent details new AMP-activated protein kinase (AMPK) activators reported to be useful for the treatment of type 2 diabetes, allergy, cancer, depression, nutrition disorders, obesity, psoriasis and ulcerative colitis, among others.
Recent Kallyope Inc. patents report AMP-activated protein kinase (AMPK) activators potentially useful for the treatment of allergy, cancer, depression, diabetes type 2, nutrition disorders, obesity, psoriasis, inflammatory bowel disease, metabolic syndrome, nonalcoholic steatohepatitis, Alzheimer’s and Parkinson’s disease, among others.
Kallyope Inc. has synthesized glucose-dependent insulinotropic receptor (GDIR; GPR119) agonists reported to be useful for the treatment of metabolic and nutrition disorders.
Kallyope Inc., a company leveraging connections between the gut and brain to develop new medicines for diabetes, obesity and other diseases, has raised $236 million in series D financing to support its work. Readouts of early clinical data for its most advanced programs, phase I small molecules for metabolic disease and gut barrier conditions, will start to arrive later this year, company CEO and President Jay Galeota told BioWorld.
